Thomas R. Beck

Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.

Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.

Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the board of Adagene, Ltd. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics.

Thomas R. Beck is the Executive Partner at F-Prime Capital, based in United States, North America. With a background in Financial Services, Thomas R. Beck has a rich history of leadership and innovation. Thomas R. Beck studied BS unknown @ Yale University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.